Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats

被引:0
|
作者
Dirig, DM
Isakson, PC
Yaksh, TL
机构
[1] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Intrathecal administration of nonsteroidal anti-inflammatory drugs in the rat blocks the thermal hyperalgesia induced by tissue injury, which suggests a role for spinal cyclooxygenase (COX) products in this facilitated state. Two isozymes of the COX enzyme have been reported, COX-1 and COX-2, but the agents thus far examined are not isozyme selective. We examined the effects of intrathecally (i.t.) or systemically (i.p.) administered S(+)-ibuprofen (a nonselective COX inhibitor) or 1-[(4-methysulfonyl)phenyl]-3-tri-fluoromethyl-5-(4-fluorophenyl)pyrazole (SC58125; a COX-2 selective inhibitor) on carrageenan-induced thermal hyperalgesia (reduced hindpaw-withdrawal latency). The following observations were made: 1) Thermal hyperalgesia otherwise observed during the first 170 min was blocked in a dose-dependent manner by S(+)-ibuprofen or SC58125 administered i.t. or i.p. before carrageenan treatment. 2) Intraperitoneal, but not i.t., administration of either inhibitor after the establishment of hyperalgesia (170 min after carrageenan injection) reversed thermal hyperalgesia in a dose-dependent manner. Thus, the initial component of thermal hyperalgesia after tissue injury was blocked by systemic or spinal administration of both COX inhibitors, whereas established hyperalgesia was reversed only by systemic inhibitors. This study demonstrates that at least spinal COX-2, if not both COX-1 and COX-2, are necessary for the initiation of thermal hyperalgesia, whereas nonspinal sources of prostanoids (synthesized by COX-2 and perhaps also COX-1) are important for the maintenance of thermal hyperalgesia associated with tissue injury and inflammation.
引用
收藏
页码:1031 / 1038
页数:8
相关论文
共 50 条
  • [41] Development of more selective NSAIDS: Cox-1 and Cox-2
    Barragry, T
    IRISH VETERINARY JOURNAL, 1996, 49 (09) : 553 - &
  • [42] Carcinogen substrate specificity of human COX-1 and COX-2
    Wiese, FW
    Thompson, PA
    Kadlubar, FF
    CARCINOGENESIS, 2001, 22 (01) : 5 - 10
  • [43] Distribution of COX-1 and COX-2 in normal and inflamed tissues
    Seibert, K
    Zhang, Y
    Leahy, K
    Hauser, S
    Masferrer, J
    Isakson, P
    EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY 2, PTS A AND B, 1997, 400 : 167 - 170
  • [44] Does the COX-1/COX-2 concept still hold?
    Hawkey, C
    UPDATE GASTROENTEROLOGY 2004: NEW DEVELOPMENTS IN THE MANAGEMENT OF BENIGN GASTROINTESTINAL DISORDERS, 2004, : 87 - 89
  • [45] The role of COX-1 and COX-2 isozymes in experimental cholera
    Gessell-Lee, DL
    Peterson, JW
    GASTROENTEROLOGY, 2001, 120 (05) : A323 - A323
  • [46] COX-2, but not COX-1, is involved in mechanotransduction in bone cells
    Bakker, AD
    Burger, EH
    Semeins, CM
    Klein-Nulend, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S215 - S215
  • [47] The pyrrole moiety as a template for COX-1/COX-2 inhibitors
    Dannhardt, G
    Kiefer, W
    Krämer, G
    Maehrlein, S
    Nowe, U
    Fiebich, B
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2000, 35 (05) : 499 - 510
  • [48] Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques
    McGeer, PL
    McGeer, EG
    Yasojima, K
    EXPERIMENTAL GERONTOLOGY, 2002, 37 (07) : 925 - 929
  • [49] Structure of COX-1 and COX-2 enzymes and their interaction with inhibitors
    Bakhle, YS
    DRUGS OF TODAY, 1999, 35 (4-5): : 237 - 250
  • [50] COX-1 and COX-2 tissue expression: Implications and predictions
    Crofford, LJ
    JOURNAL OF RHEUMATOLOGY, 1997, 24 : 15 - 19